Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avicena Group, Inc.
Avicena's Nurigene products demonstrate anti-aging properties in clinical study
June 23rd, 2006
The Avicena Group, Inc., (AVGO) a developer of pharmaceutical and therapeutic products, announced positive findings from a clinical study of its Nurigene dermaceutical product line. Results demonstrated that skin treated with Nurigene, which incorporates Avicena's proprietary MgA technology, experienced a statistically significant increase in cell turnover versus untreated skin, with some subjects in the study experiencing up to a 43% increase in cell renewal. Cell turnover is a continual process by which old skin cells are replaced with newer, more vibrant cells. An increase in the rate of this process is an indication of how often skin is regenerated. ...
Source: Biotech Law Weekly (2006-06-23)
|
